CD38 and plasma cell myeloma: As a monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least 4 prior therapies and whose disease is refractory to at least one proteasome inhibitor/immunomodulator/CD38 monoclonal antibody, and whose disease progression was demonstrated on their last therapy